The SLC26A4 gene encodes pendrin, a transmembrane anion transporter involved in ion homeostasis. Mutations in SLC26A4 are linked to hearing loss and thyroid dysfunction, notably in Pendred syndrome and non-syndromic enlarged vestibular aqueduct (EVA). Pendrin facilitates chloride/iodide, bicarbonate, and other anion exchanges, playing critical roles in endolymphatic fluid pH regulation in the inner ear and iodide organification in the thyroid. Dysfunctional pendrin disrupts ion balance, leading to inner ear malformations, hearing impairment, and goiter.
Antibodies targeting SLC26A4/pendrin are essential tools for studying its expression, localization, and function in tissues. They are widely used in immunohistochemistry, Western blotting, and immunofluorescence to analyze pendrin distribution in murine or human samples, particularly in cochlear, renal, and thyroid tissues. These antibodies help validate disease models, assess protein expression levels in mutation carriers, and investigate pendrin's interaction with other proteins (e.g., FOXI1 transcription factor). Commercially available antibodies vary in specificity, often requiring validation via knockout controls. Research utilizing these antibodies has advanced our understanding of SLC26A4-related pathologies, aiding in diagnostic approaches and potential therapeutic strategies targeting pendrin dysfunction.